FDA Approval: Blinatumomab

On December 3, 2014, the FDA granted accelerated approval of blinatumomab (Blincyto; Amgen, Inc.) for treatment of Philadelphia chromosome-negative relapsed or refractory precursor B-cell acute lymphoblastic leukemia (R/R ALL). Blinatumomab is a recombinant murine protein that acts as a bispecific C...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2015-09, Vol.21 (18), p.4035-4039
Hauptverfasser:	Przepiorka, Donna, Ko, Chia-Wen, Deisseroth, Albert, Yancey, Carolyn L, Candau-Chacon, Reyes, Chiu, Haw-Jyh, Gehrke, Brenda J, Gomez-Broughton, Candace, Kane, Robert C, Kirshner, Susan, Mehrotra, Nitin, Ricks, Tiffany K, Schmiel, Deborah, Song, Pengfei, Zhao, Ping, Zhou, Qing, Farrell, Ann T, Pazdur, Richard
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Animals Antibodies, Bispecific - adverse effects Antibodies, Bispecific - chemistry Antibodies, Bispecific - pharmacology Antigens, CD19 - metabolism Antineoplastic Agents - adverse effects Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology CD3 Complex - metabolism Clinical Trials as Topic Cytokines - metabolism Disease-Free Survival Drug Approval Female Hematopoietic Stem Cell Transplantation Humans Male Mice Middle Aged Neoplasm, Residual Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - therapy Recurrence Remission Induction Treatment Outcome United States United States Food and Drug Administration
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!